BCL2 and hepatocellular carcinoma: Our data provide evidence that simultaneously targeting Bcl-2 and Mcl-1 with BH3-mimetics is successful across different HCC cell lines, irrespective of the p53 status (HepG2: wtp53, Hep3B: deleted p53 and Huh7: mutated p53) and Bcl-XL and NOXA expression.